ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
ENDONOVO THERAPEUTICS, INC.
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $135.08K
- P/E (TTM)
- –
- Dividend yield
- –
ENDONOVO THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|
| Royalty [Member] | $113.62K | – | – | – | – | 83.9% | – |
| Direct Sales Medical Care Providers Gross [Member] | $21.73K | $73.11K | $165.80K | – | – | 16.1% | -70.3% |
| Product [Member] | – | – | – | – | $17.05K | – | – |
| Gross Revenue [Member] | – | – | – | – | $66.22K | – | – |
| Distributor- Plastic Surgeons, Net [Member] | – | – | – | – | $17.05K | – | – |
| Direct Sales - Plastic Surgeons, Gross [Member] | – | – | $165.80K | $310.16K | $66.22K | – | – |
By region
From the segment and revenue-disaggregation notes of Endonovo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.